In vivo modulation of the behavioral effects of nicotine by the coumarins xanthotoxin, bergapten, and umbelliferone

被引:27
作者
Budzynska, Barbara [1 ]
Skalicka-Wozniak, Krystyna [2 ]
Kruk-Slomka, Marta [1 ]
Wydrzynska-Kuzma, Malgorzata [1 ]
Biala, Grazyna [1 ]
机构
[1] Med Univ Lublin, Dept Pharmacol & Pharmacodynam, Lublin, Poland
[2] Med Univ Lublin, Dept Pharmacognosy, Med Plants Unit, Lublin, Poland
关键词
Coumarins; Nicotine; Memory; Depression; Mice; CALCIUM-CHANNEL ANTAGONISTS; INDUCED MEMORY IMPAIRMENT; ANTICONVULSANT ACTIVITY; NITRIC-OXIDE; METABOLISM; CYP2A6; METHOXSALEN; IMPERATORIN; MOUSE; SCOPOLAMINE;
D O I
10.1007/s00213-016-4279-9
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Nicotine, a dominant alkaloid found in tobacco, is responsible for physical dependence, as well as addiction to cigarette smoking; consequently, smoking cessation is a very difficult process. Hepatic cytochrome P-450 2A6 (CYP2A6) is involved in the 70-80 % of the initial metabolism of nicotine and its co-metabolites. As this metabolism is slowed by inhibitors of CYP2A6, this kind of enzymatic inhibition has been proposed as a novel target for smoking cessation. Nicotine administered alone improved memory acquisition and consolidation as well as exerted antidepressive activity in animal models. These effects persist for 24 h. However, they are completely extinguished 48 h after administration. To investigate if the coumarins prolong the behavioral effects of nicotine, the forced swimming test (FST)-animal models of depression, and passive avoidance (PA) test-memory and learning paradigm were used. This study revealed that three CYP2A6 inhibitors: two furanocoumarins, xanthotoxin (15 mg/kg) and bergapten (25 mg/kg), and the simple coumarin umbelliferone (25 mg/kg), prolonged the antidepressive and procognitive effects of nicotine. These natural products may offer a new approach to the treatment of nicotinism as antidepressant and memory improvement actions are one of the main factors of nicotine dependence.
引用
收藏
页码:2289 / 2300
页数:12
相关论文
共 60 条
[1]  
Abed MJ, 2001, J PHARM PHARMACOL, V53, P163
[2]   Molecular mechanisms of memory acquisition, consolidation and retrieval [J].
Abel, T ;
Lattal, KM .
CURRENT OPINION IN NEUROBIOLOGY, 2001, 11 (02) :180-187
[3]   Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors [J].
Al Koudsi, Nael ;
Hoffmann, Ewa B. ;
Assadzadeh, Abbas ;
Tyndale, Rachel F. .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (03) :239-251
[4]   Suppression of nitric oxide synthesis by L-NAME reverses the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice [J].
Allami, Nika ;
Javadi-Paydar, Mehrak ;
Rayatnia, Farhoud ;
Sehhat, Kourosh ;
Rahimian, Reza ;
Norouzi, Abbas ;
Dehpour, Ahmad Reza .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2011, 650 (01) :240-248
[5]   Pharmacokinetic and Pharmacodynamics Studies of Nicotine After Oral Administration in Mice: Effects of Methoxsalen, a CYP2A5/6 Inhibitor [J].
Alsharari, Shakir D. ;
Siu, Eric C. K. ;
Tyndale, Rachel F. ;
Damaj, Mohamad Imad .
NICOTINE & TOBACCO RESEARCH, 2014, 16 (01) :18-25
[6]   Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice [J].
Bagdas, Deniz ;
Muldoon, Pretal P. ;
Zhu, Andy Z. X. ;
Tyndale, Rachel F. ;
Damaj, M. Imad .
NEUROPHARMACOLOGY, 2014, 85 :67-72
[7]   Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics [J].
Benowitz, Neal L. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2009, 49 :57-71
[8]   Dopamine and Memory: Modulation of the Persistence of Memory for Novel Hippocampal NMDA Receptor-Dependent Paired Associates [J].
Bethus, Ingrid ;
Tse, Dorothy ;
Morris, Richard G. M. .
JOURNAL OF NEUROSCIENCE, 2010, 30 (05) :1610-1618
[9]   Influence of calcium channel antagonists on nonsomatic signs of nicotine and D-amphetamine withdrawal in mice [J].
Biala, Grazyna ;
Polak, Piotr ;
Michalak, Agnieszka ;
Kruk-Slomka, Marta ;
Budzynska, Barbara .
PHARMACOLOGICAL REPORTS, 2014, 66 (02) :212-222
[10]   THE NONCOMPETITIVE AMPA/KAINATE RECEPTOR ANTAGONIST, GYKI-52466, POTENTIATES THE ANTICONVULSANT ACTIVITY OF CONVENTIONAL ANTIEPILEPTICS [J].
BOROWICZ, KK ;
GASIOR, M ;
KLEINROK, Z ;
CZUCZWAR, SJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 281 (03) :319-326